Spots Global Cancer Trial Database for A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
Official Title: A Phase 1，Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-421286 in Subjects With Advanced Solid Tumors
Study ID: NCT05315180
Interventions
Study Description
Brief Summary: Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shun Lu, Ph.D, Shanghai, Shanghai, China
Dingzhi Huang, Ph.D, Tianjin, Tianjin, China
Wen Li, Ph.D, Hangzhou, Zhejiang, China
Yun Fan,Ph.D, Hangzhou, Zhejiang, China
Shun Lu, Ph.D, Shanghai, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
